Dual effects of phytoestrogens result in u-shaped dose-response curves.
Open Access
- 1 August 2002
- journal article
- Published by Environmental Health Perspectives in Environmental Health Perspectives
- Vol. 110 (8), 743-748
- https://doi.org/10.1289/ehp.02110743
Abstract
Endocrine disruptors can affect the endocrine system without directly interacting with receptors, for example, by interfering with the synthesis or metabolism of steroid hormones. The aromatase that converts testosterone to 17beta-estradiol is a possible target. In this paper we describe an assay that simultaneously detects aromatase inhibition and estrogenicity. The principle is similar to that of other MCF-7 estrogenicity assays, but with a fixed amount of testosterone added. The endogenous aromatase activity in MCF-7 cells converts some of the testosterone to 17beta-estradiol, which is assayed by quantifying differences in the expression level of the estrogen-induced pS2 mRNA. Potential aromatase inhibitors can be identified by a dose-dependent reduction in the pS2 mRNA expression level after exposure to testosterone and the test compound. Using this assay, we have investigated several compounds, including synthetic chemicals and phytoestrogens, for aromatase inhibition. The phytoestrogens, except genistein, were aromatase inhibitors at low concentrations (< 1 micro M) but estrogenic at higher concentrations (greater than or equal to 1 micro M), resulting in U-shaped dose-response curves. None of the tested synthetic chemicals were aromatase inhibitors. The low-dose aromatase inhibition distinguished phytoestrogens from other estrogenic compounds and may partly explain reports about antiestrogenic properties of phytoestrogens. Aromatase inhibition may play an important role in the protective effects of phytoestrogens against breast cancer.Keywords
This publication has 48 references indexed in Scilit:
- A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trialThe Lancet, 2001
- Bone Has a Sexually Dimorphic Response to Aromatase DeficiencyJournal of Bone and Mineral Research, 2000
- Effects of phytoestrogens on aromatase, 3β and 17β-hydroxysteroid dehydrogenase activities and human breast cancer cellsLife Sciences, 2000
- Rethinking breast cancer risk and the environment: the case for the precautionary principle.Environmental Health Perspectives, 1998
- The preclinical pharmacology of “Arimidex” (Anastrozole; ZD1033) — a potent, selective aromatase inhibitorThe Journal of Steroid Biochemistry and Molecular Biology, 1996
- Effects of flavonoids on aromatase activity, an in vitro studyThe Journal of Steroid Biochemistry and Molecular Biology, 1996
- The control and biological importance of intratumoural aromatase in breast cancerThe Journal of Steroid Biochemistry and Molecular Biology, 1996
- Development of cytochrome P450 aromatase mRNA levels and enzyme activity in ovaries of normal and hypogonadal (hpg) miceJournal of Molecular Endocrinology, 1995
- Growth suppression of MCF-7 human breast cancer cells by aromatase inhibitors: A new system for aromatase inhibitor screeningThe Journal of Steroid Biochemistry and Molecular Biology, 1993
- Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogensThe Journal of Steroid Biochemistry and Molecular Biology, 1993